• Xenon Pharmaceuticals (XENE) Phase 2b Results of TV-45070 for Post-Herpetic Neuralgia

       (0 reviews)

    Biotech_Forecast
    Clinical and Regulatory
    Event Type: Phase 2b Results
    Timing: H1 2017
    Designation(s): None

    This event is set for a broad date range and therefore the exact timing is unknown. This adds a degree of risk.
    FDA special designations may increase the likelihood of success and decrease the time to approval.
    Learn More

    Disease and Treatment
    Disease: Neurology
    Indication: Post-Herpetic Neuralgia
    Lead Indication?: No
    Treatment Name: TV-45070

    Likelihood of event success varies depending on disease, treatment and lead indication classification.
    Learn More

    Company Information
    Co. Name: Xenon Pharmaceuticals
    Stock Symbol: XENE
    Shares Traded: NASDAQ

    The OTC BB and OTC Markets have less stringent reporting and financial requirements than the NASDAQ and NYSE. This may increase the level of risk for investors. Smaller size may have an influence on likelihood of success.
    Learn More

    Event Status
    Event Outcome: Ongoing
    Event Discussion: Forums
    Event Announcement(s): http://investor.xenon-pharma.com/phoenix.zhtml?c=253202&p=irol-newsArticle&ID=2167109
    Partnership: Yes

    Partnerships help smaller biotech companies finance the long approval process. Partnership also provides validation the clinical program may be a worthy investment.
    Learn More

    Detailed Event Description from Company Announcement

     

    Quote

    Partnered Programs

    • Xenon's partner Teva Pharmaceutical Industries Ltd. is currently conducting a randomized, double-blind, placebo-controlled Phase 2b clinical trial for TV-45070 in patients with post-herpetic neuralgia, with results expected in the first half of 2017.

     

     

     

     


      Report Event


    User Feedback

    There are no reviews to display.